ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 617

The Potentiality Of Multi-Target Therapy With Cyclophosphamide and Tacrolimus For Lupus Nephritis

Ryota Sakai, Akiko Shibata, Kentaro Chino, Tsuneo Kondo, Ayumi Okuyama, Eiko Nishi, Hirofumi Takei, Hayato Nagasawa and Koichi Amano, Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cyclophosphamide, lupus nephritis and tacrolimus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Multi-target therapy for lupus nephritis (LN) had first reported by Bao et al. 2008 regarding the treatment of mixed diffuse proliferative and membranous LN using a combination of corticosteroids, mycophenolate mofetil and tacrolimus (Tac). Following this, several studies had suggested the efficacy of combination therapies utilizing two or more immunosuppressive agents with different mechanisms of action. The objective of this retrospective study is to assess the effectiveness of multi-target therapy with cyclophosphamide (CY) and Tac for class III and IV LN as a remission induction therapy in our single center experience and to discuss the potentiality of this multi-target therapy with renal pathological findings.

Methods: We evaluated 43 patients with active LN who performed renal biopsies at Saitama Medical Center between January 2007 and August 2012. The complete renal remission was defined as spot urine protein: creatinine ratio <0.5g/gCr or under plus and minus values in urinalysis and normal GFR or improvement of GFR according to the EULAR/ERA-EDTA recommendation. Renal pathological findings were assessed according to the 2003 ISN/RPS classification for LN. Crescents, fibrinoid necrosis, interstitial cell infiltration and chronicity were evaluated as well.

Results: The number of patients in each class was as follows; II: 9, III: 4, IV: 28, V: 2. In 32 cases with class III/IV, crescents: 15 (46.9%), fibrinoid necrosis: 8 (25.0%), interstitial cell infiltration: 15 (46.9%) and chronicity: 18 (56.3%). Four cases (12.5%) had membranous nephropathy (Class IV + V). CY was initiated in 24 cases with class III/IV. Eleven out of 24 (45.8%) cases received multi-target therapy with Tac (CY + Tac group) as a remission induction therapy. In the other 13 (54.2%) cases various immunosuppressants (Tac, azathioprine, cyclosporine, mizoribine pulse) were prescribed as a maintenance therapy after CY (CY-IS group). The complete remission rate at 12 months was 45.5% in CY + Tac group and 69.2% in CY-IS group (p=0.41). However patients’ background of each group was quite different. Although chronicity was observed more commonly in CY + Tac group (p=0.047), the remission rate in patients with chronicity was 44.4% in CY + Tac group and 20.0% in CY-IS group (p=0.58).

Conclusion: Multi-target therapy such as CY + Tac may be effective for refractory LN with chronicity in renal pathological findings.


Disclosure:

R. Sakai,
None;

A. Shibata,
None;

K. Chino,
None;

T. Kondo,
None;

A. Okuyama,
None;

E. Nishi,
None;

H. Takei,
None;

H. Nagasawa,
None;

K. Amano,

Chugai,

2,

Astellas,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-potentiality-of-multi-target-therapy-with-cyclophosphamide-and-tacrolimus-for-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology